Abcely is a health biotechnology start-up specializing in the development of a completely new class of therapeutic molecules, orally-active class A immunoglobulins. These molecules have a tropism of distribution and action in all the mucous membranes of the body. (digestive, respiratory, urogenital tract and associated glandular systems such as the breast or prostate).
The drug candidate developed by Abcely, ABC-101, is the first class A, orally active monoclonal antibody directed against a tumor marker that is extremely well validated in oncology: CEA (Carcino-Embryo Antigen). CEA was chosen as a target because many digestive and mucosal cancers (lungs, urogenital tract and associated glands) overexpress this marker during cancerous transformation.
Abcely is also involved in the R&D of IgA applied to the field of endometriosis treatment, a very disabling pathology affecting approximately 10% of women.

Abcely’s mission is to develop new innovative medical and pharmaceutical technologies in the field of the treatment of mucosal cancers, thus offering patients in therapeutic impasse a new solution based on a brand-new concept of immunotherapy in cancerology. The unique concept developed by Abcely is based on the use of a new class of orally active therapeutic molecules (IgA). Abcely is involved in all phases of development, from the identification of compounds of biological origin as potential active ingredients to the demonstration of their activity in the human clinic. Abcely’ positioning in the competitive landscape is unique since no other orally-active IgA is being developed in oncology or any other indication.

–  Therapeutic areas: oncology, immotherapy, endometriosis, inflammation

–  Based in: Nantes (FRANCE)

–  Employees: 1-10

– Created in: 2022